Edgar Filing: CONMED CORP

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

CORASANTI JOSEPH J

2. Issuer Name and Ticker or Trading Symbol
CONMED CORP [CNMD]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Former President & CEO

(Last)

(First)

(Middle)

101 WINSHIP ROAD

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2014

(Street)

NEW HARTFORD, NY 13413

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/30/2014		M		5,000	A	$ 0	137,685	D
Common Stock	07/30/2014		F		2,534	D	$ 39.38	135,151	D
Common Stock	07/30/2014		M		10,000	A	$ 0	145,151	D
Common Stock	07/30/2014		F		5,067	D	$ 39.38	140,084	D
Common Stock	07/30/2014		M		15,000	A	$ 0	155,084	D
Common Stock	07/30/2014		F		7,601	D	$ 39.38	147,483	D
Common Stock	07/30/2014		M		20,000	A	$ 0	167,483	D
Common Stock	07/30/2014		F		10,134	D	$ 39.38	157,349	D
Common Stock	07/30/2014		M		16,250	A	$ 0	173,599	D
Common Stock	07/30/2014		F		8,234	D	$ 39.38	165,365	D
Common Stock	07/30/2014		M		62,500	A	$ 19.93	227,865	D
Common Stock	07/30/2014		F		47,273	D	$ 39.38	180,592	D
Common Stock	07/30/2014		M		62,500	A	$ 29.92	243,092	D
Common Stock	07/30/2014		F		55,095	D	$ 39.38	187,997	D
Common Stock	07/30/2014		M		62,500	A	$ 26.69	250,497	D
Common Stock	07/30/2014		F		52,566	D	$ 39.38	197,931	D
Common Stock	07/30/2014		M		62,500	A	$ 16.46	260,431	D
Common Stock	07/30/2014		F		44,556	D	$ 39.38	215,875	D
Common Stock	07/30/2014		M		40,000	A	$ 21.19	255,875	D
Common Stock	07/30/2014		F		30,886	D	$ 39.38	224,989	D
Common Stock	07/30/2014		M		62,500	A	$ 19.26	287,489	D
Common Stock	07/30/2014		F		46,749	D	$ 39.38	240,740	D
Common Stock	07/30/2014		M		62,500	A	$ 27.63	303,240	D
Common Stock	07/30/2014		F		53,302	D	$ 39.38	249,938	D
Common Stock	07/30/2014		M		62,500	A	$ 26.09	312,438	D
Common Stock	07/30/2014		F		52,096	D	$ 39.38	260,342	D
Common Stock	07/30/2014		M		62,500	A	$ 32.93	322,842	D
Common Stock	07/30/2014		F		57,451	D	$ 39.38	265,391	D
Common Stock	07/30/2014		S		109,035	D	$ 39.2483 ⁽¹⁾	156,356	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Rsus (restricted Stock Units)

$ 0

07/30/2014

5,000

⁽²⁾⁽³⁾

06/01/2020

Common Stock

5,000

$ 0

Rsus (restricted Stock Units)

$ 0

07/30/2014

10,000

⁽²⁾⁽³⁾

06/01/2021

Common Stock

10,000

$ 0

Rsus (restricted Stock Units)

$ 0

07/30/2014

15,000

⁽²⁾⁽³⁾

06/01/2022

Common Stock

15,000

$ 0

Rsus (restricted Stock Units)

$ 0

07/30/2014

20,000

⁽²⁾⁽³⁾

06/01/2023

Common Stock

20,000

$ 0

Rsus (restricted Stock Units)

$ 0

07/30/2014

16,250

⁽²⁾⁽³⁾

06/01/2024

Common Stock

16,250

$ 0

Sars (Stock Appreciation Rights)

$ 19.93

07/30/2014

62,500

⁽³⁾⁽⁴⁾

05/16/2016

Common Stock

62,500

$ 0

Sars (Stock Appreciation Rights)

$ 29.92

07/30/2014

62,500

⁽³⁾⁽⁵⁾

05/17/2017

Common Stock

62,500

$ 0

Sars (Stock Appreciation Rights)

$ 26.69

07/30/2014

62,500

⁽³⁾⁽⁵⁾

06/01/2018

Common Stock

62,500

$ 0

Sars (Stock Appreciation Rights)

$ 16.46

07/30/2014

62,500

⁽³⁾⁽⁶⁾

06/01/2019

Common Stock

62,500

$ 0

Sars (Stock Appreciation Rights)

$ 21.19

07/30/2014

40,000

⁽³⁾⁽⁷⁾

10/30/2019

Common Stock

40,000

$ 0

Sars (Stock Appreciation Rights)

$ 19.26

07/30/2014

62,500

⁽³⁾⁽⁶⁾

06/01/2020

Common Stock

62,500

$ 0

Sars (Stock Appreciation Rights)

$ 27.63

07/30/2014

62,500

⁽³⁾⁽⁶⁾

06/01/2021

Common Stock

62,500

$ 0

Sars (Stock Appreciation Rights)

$ 26.09

07/30/2014

62,500

⁽³⁾⁽⁶⁾

06/01/2022

Common Stock

62,500

$ 0

Sars (Stock Appreciation Rights)

$ 32.93

07/30/2014

62,500

⁽³⁾⁽⁶⁾

06/01/2023

Common Stock

62,500

$ 0

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
CORASANTI JOSEPH J 101 WINSHIP ROAD NEW HARTFORD, NY 13413			Former President & CEO

Signatures

Daniel S. Jonas for Joseph J. Corasanti by Power of Attorney		07/31/2014
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.35. Full information regarding the number of shares sold at each separate price will be provided upon request of the commission staff, ConMed, or a ConMed security holder.
(2)	Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 1999 Amended and Restated Long-Term Incentive Plan, with the RSUs generally vesting over a five year period with the first 20% of the RSU's vesting one year after the grant date.
(3)	According to Section 2(d) of the Separation and Release Agreement dated July 22, 2014, and attached as Exhibit 10.1 of the Form 8-K dated July 23, 2014, all of Mr. Joseph Corasanti's unvested RSUs and SARs accelerated, other than the 2014 SARS which were cancelled.
(4)	The stock appreciation rights ("SARs") were granted under the Issuer's 2006 Stock Incentive Plan and generally vest in equal amounts over a five year period.
(5)	The stock appreciation rights ("SARs") were granted under the Company's 2006 Stock Incentive Plan and generally vest in equal amounts over a five year period.
(6)	The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.
(7)	The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a period with the first 20% tranche to vest on June 1, 2010 with each successive 20% tranche to vest on June 1 the following year.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.